Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.

Zhang Y, Wester L, He J, Geiger T, Moerkens M, Siddappa R, Helmijr JA, Timmermans MM, Look MP, van Deurzen CHM, Martens JWM, Pont C, de Graauw M, Danen EHJ, Berns EMJJ, Meerman JHN, Jansen MPHM, van de Water B.

Oncogene. 2018 Apr;37(14):1869-1884. doi: 10.1038/s41388-017-0027-9. Epub 2018 Jan 22.

PMID:
29353882
2.

A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer.

Coppola S, Carnevale I, Danen EHJ, Peters GJ, Schmidt T, Assaraf YG, Giovannetti E.

Drug Resist Updat. 2017 Mar;31:43-51. doi: 10.1016/j.drup.2017.07.001. Epub 2017 Jul 24. Review.

PMID:
28867243
3.

NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.

Peterse EFP, van den Akker BEWM, Niessen B, Oosting J, Suijker J, de Jong Y, Danen EHJ, Cleton-Jansen AM, Bovée JVMG.

Mol Cancer Res. 2017 Dec;15(12):1714-1721. doi: 10.1158/1541-7786.MCR-17-0293. Epub 2017 Aug 31.

PMID:
28860121
4.

Deciphering Epithelial-Mesenchymal Transition Regulatory Networks in Cancer through Computational Approaches.

Burger GA, Danen EHJ, Beltman JB.

Front Oncol. 2017 Aug 3;7:162. doi: 10.3389/fonc.2017.00162. eCollection 2017. Review.

5.

Phenotypic screening of cannabinoid receptor 2 ligands shows different sensitivity to genotype.

Hillger JM, le Roy B, Wang Z, Mulder-Krieger T, Boomsma DI, Slagboom PE, Danen EHJ, IJzerman AP, Heitman LH.

Biochem Pharmacol. 2017 Apr 15;130:60-70. doi: 10.1016/j.bcp.2017.01.014. Epub 2017 Jan 31.

6.

Cellular adhesome screen identifies critical modulators of focal adhesion dynamics, cellular traction forces and cell migration behaviour.

Fokkelman M, Balcıoğlu HE, Klip JE, Yan K, Verbeek FJ, Danen EH, van de Water B.

Sci Rep. 2016 Aug 17;6:31707. doi: 10.1038/srep31707.

7.

No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone.

Peterse EF, Cleven AH, De Jong Y, Briaire-de Bruijn I, Fletcher JA, Danen EH, Cleton-Jansen AM, Bovée JV.

BMC Cancer. 2016 Jul 14;16:475. doi: 10.1186/s12885-016-2522-8.

8.

Targeting survivin as a potential new treatment for chondrosarcoma of bone.

de Jong Y, van Oosterwijk JG, Kruisselbrink AB, Briaire-de Bruijn IH, Agrogiannis G, Baranski Z, Cleven AH, Cleton-Jansen AM, van de Water B, Danen EH, Bovée JV.

Oncogenesis. 2016 May 9;5:e222. doi: 10.1038/oncsis.2016.33.

9.

Tumor-induced remote ECM network orientation steers angiogenesis.

Balcioglu HE, van de Water B, Danen EH.

Sci Rep. 2016 Mar 2;6:22580. doi: 10.1038/srep22580.

10.

MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation.

Baranski Z, Booij TH, Kuijjer ML, de Jong Y, Cleton-Jansen AM, Price LS, van de Water B, Bovée JV, Hogendoorn PC, Danen EH.

Genes Cancer. 2015 Nov;6(11-12):503-12.

11.

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.

Baranski Z, de Jong Y, Ilkova T, Peterse EF, Cleton-Jansen AM, van de Water B, Hogendoorn PC, Bovée JV, Danen EH.

Oncotarget. 2015 Nov 3;6(34):36113-25. doi: 10.18632/oncotarget.5333.

12.

A guide to mechanobiology: Where biology and physics meet.

Jansen KA, Donato DM, Balcioglu HE, Schmidt T, Danen EH, Koenderink GH.

Biochim Biophys Acta. 2015 Nov;1853(11 Pt B):3043-52. doi: 10.1016/j.bbamcr.2015.05.007. Epub 2015 May 18. Review.

13.

Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma.

Baranski Z, Booij TH, Cleton-Jansen AM, Price LS, van de Water B, Bovée JV, Hogendoorn PC, Danen EH.

J Pathol. 2015 Jul;236(3):348-59. doi: 10.1002/path.4528. Epub 2015 Mar 30.

PMID:
25757065
14.

Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies.

Heslop JA, Hammond TG, Santeramo I, Tort Piella A, Hopp I, Zhou J, Baty R, Graziano EI, Proto Marco B, Caron A, Sköld P, Andrews PW, Baxter MA, Hay DC, Hamdam J, Sharpe ME, Patel S, Jones DR, Reinhardt J, Danen EH, Ben-David U, Stacey G, Björquist P, Piner J, Mills J, Rowe C, Pellegrini G, Sethu S, Antoine DJ, Cross MJ, Murray P, Williams DP, Kitteringham NR, Goldring CE, Park BK.

Stem Cells Transl Med. 2015 Apr;4(4):389-400. doi: 10.5966/sctm.2014-0110. Epub 2015 Feb 26. Review.

15.

The integrin expression profile modulates orientation and dynamics of force transmission at cell-matrix adhesions.

Balcioglu HE, van Hoorn H, Donato DM, Schmidt T, Danen EH.

J Cell Sci. 2015 Apr 1;128(7):1316-26. doi: 10.1242/jcs.156950. Epub 2015 Feb 6.

16.

The E3 ubiquitin ligase ARIH1 protects against genotoxic stress by initiating a 4EHP-mediated mRNA translation arrest.

von Stechow L, Typas D, Carreras Puigvert J, Oort L, Siddappa R, Pines A, Vrieling H, van de Water B, Mullenders LH, Danen EH.

Mol Cell Biol. 2015 Apr;35(7):1254-68. doi: 10.1128/MCB.01152-14. Epub 2015 Jan 26.

17.

SYK is a candidate kinase target for the treatment of advanced prostate cancer.

Ghotra VP, He S, van der Horst G, Nijhoff S, de Bont H, Lekkerkerker A, Janssen R, Jenster G, van Leenders GJ, Hoogland AM, Verhoef EI, Baranski Z, Xiong J, van de Water B, van der Pluijm G, Snaar-Jagalska BE, Danen EH.

Cancer Res. 2015 Jan 1;75(1):230-40. doi: 10.1158/0008-5472.CAN-14-0629. Epub 2014 Nov 11.

18.

Ignoring matrix boundaries when the LKB1 master kinase is gone.

Danen EH.

J Cell Biol. 2014 Oct 27;207(2):167-9. doi: 10.1083/jcb.201409107.

19.

β1 integrin inhibition elicits a prometastatic switch through the TGFβ-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer.

Truong HH, Xiong J, Ghotra VP, Nirmala E, Haazen L, Le Dévédec SE, Balcioğlu HE, He S, Snaar-Jagalska BE, Vreugdenhil E, Meerman JH, van de Water B, Danen EH.

Sci Signal. 2014 Feb 11;7(312):ra15. doi: 10.1126/scisignal.2004751.

PMID:
24518294
20.

Unraveling DNA damage response-signaling networks through systems approaches.

von Stechow L, van de Water B, Danen EH.

Arch Toxicol. 2013 Sep;87(9):1635-48. doi: 10.1007/s00204-013-1106-5. Epub 2013 Aug 13. Review.

PMID:
23943208
21.

Targeted radiosensitization in prostate cancer.

Ghotra VP, Geldof AA, Danen EH.

Curr Pharm Des. 2013;19(15):2819-28. Review.

PMID:
23448469
22.

Integrin signaling in control of tumor growth and progression.

Xiong J, Balcioglu HE, Danen EH.

Int J Biochem Cell Biol. 2013 May;45(5):1012-5. doi: 10.1016/j.biocel.2013.02.005. Epub 2013 Feb 18. Review.

PMID:
23428797
23.

Systems biology approach identifies the kinase Csnk1a1 as a regulator of the DNA damage response in embryonic stem cells.

Carreras Puigvert J, von Stechow L, Siddappa R, Pines A, Bahjat M, Haazen LC, Olsen JV, Vrieling H, Meerman JH, Mullenders LH, van de Water B, Danen EH.

Sci Signal. 2013 Jan 22;6(259):ra5. doi: 10.1126/scisignal.2003208.

PMID:
23354688
24.

Combining doublecortin-like kinase silencing and vinca alkaloids results in a synergistic apoptotic effect in neuroblastoma cells.

Verissimo CS, Cheng S, Puigvert JC, Qin Y, Vroon A, van Deutekom J, Price LS, Danen EH, van de Water B, Fitzsimons CP, Vreugdenhil E.

J Pharmacol Exp Ther. 2012 Jul;342(1):119-30. doi: 10.1124/jpet.111.188813. Epub 2012 Apr 6.

25.

Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model.

He S, Lamers GE, Beenakker JW, Cui C, Ghotra VP, Danen EH, Meijer AH, Spaink HP, Snaar-Jagalska BE.

J Pathol. 2012 Aug;227(4):431-45. doi: 10.1002/path.4013. Epub 2012 Jul 3.

26.

Automated whole animal bio-imaging assay for human cancer dissemination.

Ghotra VP, He S, de Bont H, van der Ent W, Spaink HP, van de Water B, Snaar-Jagalska BE, Danen EH.

PLoS One. 2012;7(2):e31281. doi: 10.1371/journal.pone.0031281. Epub 2012 Feb 8.

27.

Automated microinjection of cell-polymer suspensions in 3D ECM scaffolds for high-throughput quantitative cancer invasion screens.

Truong HH, de Sonneville J, Ghotra VP, Xiong J, Price L, Hogendoorn PC, Spaink HH, van de Water B, Danen EH.

Biomaterials. 2012 Jan;33(1):181-8. doi: 10.1016/j.biomaterials.2011.09.049. Epub 2011 Oct 20.

PMID:
22018386
28.

Global phosphoproteome profiling reveals unanticipated networks responsive to cisplatin treatment of embryonic stem cells.

Pines A, Kelstrup CD, Vrouwe MG, Puigvert JC, Typas D, Misovic B, de Groot A, von Stechow L, van de Water B, Danen EH, Vrieling H, Mullenders LH, Olsen JV.

Mol Cell Biol. 2011 Dec;31(24):4964-77. doi: 10.1128/MCB.05258-11. Epub 2011 Oct 17.

29.

BMP-7 inhibits TGF-β-induced invasion of breast cancer cells through inhibition of integrin β(3) expression.

Naber HP, Wiercinska E, Pardali E, van Laar T, Nirmala E, Sundqvist A, van Dam H, van der Horst G, van der Pluijm G, Heckmann B, Danen EH, Ten Dijke P.

Cell Oncol (Dordr). 2012 Feb;35(1):19-28. doi: 10.1007/s13402-011-0058-0. Epub 2011 Sep 21.

30.

p140Cap suppresses the invasive properties of highly metastatic MTLn3-EGFR cells via impaired cortactin phosphorylation.

Damiano L, Le Dévédec SE, Di Stefano P, Repetto D, Lalai R, Truong H, Xiong JL, Danen EH, Yan K, Verbeek FJ, De Luca E, Attanasio F, Buccione R, Turco E, van de Water B, Defilippi P.

Oncogene. 2012 Feb 2;31(5):624-33. doi: 10.1038/onc.2011.257. Epub 2011 Jul 4.

PMID:
21725361
31.

RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling.

Wang Z, Collighan RJ, Gross SR, Danen EH, Orend G, Telci D, Griffin M.

J Biol Chem. 2010 Dec 17;285(51):40212-29. doi: 10.1074/jbc.M110.123703. Epub 2010 Oct 7.

32.

The interaction of SRC kinase with beta3 integrin tails: a potential therapeutic target in thrombosis and cancer.

Huveneers S, Danen EH.

ScientificWorldJournal. 2010 Jun 15;10:1100-5. doi: 10.1100/tsw.2010.114.

33.

Systems microscopy approaches to understand cancer cell migration and metastasis.

Le Dévédec SE, Yan K, de Bont H, Ghotra V, Truong H, Danen EH, Verbeek F, van de Water B.

Cell Mol Life Sci. 2010 Oct;67(19):3219-40. doi: 10.1007/s00018-010-0419-2. Epub 2010 Jun 18. Review.

34.

High-throughput live cell imaging of apoptosis.

Puigvert JC, de Bont H, van de Water B, Danen EH.

Curr Protoc Cell Biol. 2010 Jun;Chapter 18:Unit 18.10.1-13. doi: 10.1002/0471143030.cb1810s47.

PMID:
20521231
35.

Silencing of the microtubule-associated proteins doublecortin-like and doublecortin-like kinase-long induces apoptosis in neuroblastoma cells.

Verissimo CS, Molenaar JJ, Meerman J, Puigvert JC, Lamers F, Koster J, Danen EH, van de Water B, Versteeg R, Fitzsimons CP, Vreugdenhil E.

Endocr Relat Cancer. 2010 Apr 21;17(2):399-414. doi: 10.1677/ERC-09-0301. Print 2010 Jun.

PMID:
20228126
36.

The cancer stem cell microenvironment and anti-cancer therapy.

Ghotra VP, Puigvert JC, Danen EH.

Int J Radiat Biol. 2009 Nov;85(11):955-62. doi: 10.3109/09553000903242164. Review.

PMID:
19895272
37.

Integrin proteomes reveal a new guide for cell motility.

Danen EH.

Sci Signal. 2009 Sep 22;2(89):pe58. doi: 10.1126/scisignal.289pe58. Review.

PMID:
19797271
38.

Complete focal adhesion kinase deficiency in the mammary gland causes ductal dilation and aberrant branching morphogenesis through defects in Rho kinase-dependent cell contractility.

van Miltenburg MH, Lalai R, de Bont H, van Waaij E, Beggs H, Danen EH, van de Water B.

FASEB J. 2009 Oct;23(10):3482-93. doi: 10.1096/fj.08-123398. Epub 2009 Jul 7.

PMID:
19584305
39.

Adhesion signaling - crosstalk between integrins, Src and Rho.

Huveneers S, Danen EH.

J Cell Sci. 2009 Apr 15;122(Pt 8):1059-69. doi: 10.1242/jcs.039446. Review.

40.

Integrin switching modulates adhesion dynamics and cell migration.

Truong H, Danen EH.

Cell Adh Migr. 2009 Apr-Jun;3(2):179-81. Epub 2009 Apr 30. Review.

41.

Cross-talk between integrins and oncogenes modulates chemosensitivity.

Puigvert JC, Huveneers S, Fredriksson L, op het Veld M, van de Water B, Danen EH.

Mol Pharmacol. 2009 Apr;75(4):947-55. doi: 10.1124/mol.108.051649. Epub 2009 Jan 21.

42.

Binding of soluble fibronectin to integrin alpha5 beta1 - link to focal adhesion redistribution and contractile shape.

Huveneers S, Truong H, Fässler R, Sonnenberg A, Danen EH.

J Cell Sci. 2008 Aug 1;121(Pt 15):2452-62. doi: 10.1242/jcs.033001. Epub 2008 Jul 8.

43.

Integrins uncouple Src-induced morphological and oncogenic transformation.

Huveneers S, Arslan S, van de Water B, Sonnenberg A, Danen EH.

J Biol Chem. 2008 May 9;283(19):13243-51. doi: 10.1074/jbc.M800927200. Epub 2008 Mar 7.

44.

Integrin alpha v beta 3 controls activity and oncogenic potential of primed c-Src.

Huveneers S, van den Bout I, Sonneveld P, Sancho A, Sonnenberg A, Danen EH.

Cancer Res. 2007 Mar 15;67(6):2693-700.

45.

The regulation of MacMARCKS expression by integrin beta3.

van den Bout I, Truong HH, Huveneers S, Kuikman I, Danen EH, Sonnenberg A.

Exp Cell Res. 2007 Apr 1;313(6):1260-9. Epub 2007 Jan 12.

PMID:
17292354
46.

Integrins control motile strategy through a Rho-cofilin pathway.

Danen EH, van Rheenen J, Franken W, Huveneers S, Sonneveld P, Jalink K, Sonnenberg A.

J Cell Biol. 2005 May 9;169(3):515-26. Epub 2005 May 2. Erratum in: J Cell Biol. 2005 Aug 1;170(3):497.

47.

Integrins: regulators of tissue function and cancer progression.

Danen EH.

Curr Pharm Des. 2005;11(7):881-91. Review.

PMID:
15777241
48.

Integrins in regulation of tissue development and function.

Danen EH, Sonnenberg A.

J Pathol. 2003 Dec;201(4):632-41. Review.

PMID:
14648669
49.

Integrins in regulation of tissue development and function.

Danen EH, Sonnenberg A.

J Pathol. 2003 Jul;200(4):471-80. Review. Corrected and republished in: J Pathol. 2003 Dec;201(4):632-41.

PMID:
12845614
50.

Supplemental Content

Loading ...
Support Center